机构:[1]Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, Laboratory of Neuro-system and Multimorbidity, Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[2]Key Laboratory of Rehabilitation Medicine in Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院
This manuscript was supported by National Natural Science Foundation of China (Nos. 82273770 and 22377084) and the Support Program of Science & Technology Department of Sichuan Provincial (No. 2025ZNSFSC0691, China).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|1 区医学
小类|1 区药学
最新[2025]版:
大类|1 区医学
小类|1 区药学
第一作者:
第一作者机构:[1]Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, Laboratory of Neuro-system and Multimorbidity, Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Huang Chengcheng,Liang Yuxiang,Li Yang,et al.The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials[J].Acta Pharmaceutica Sinica B.2025,15(11):5601-5631.doi:10.1016/j.apsb.2025.08.022.
APA:
Huang Chengcheng,Liang Yuxiang,Li Yang,Wei Quan,Ouyang Liang&Zhang Jifa.(2025).The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials.Acta Pharmaceutica Sinica B,15,(11)
MLA:
Huang Chengcheng,et al."The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials".Acta Pharmaceutica Sinica B 15..11(2025):5601-5631